Elena Valassi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4245863/publications.pdf

Version: 2024-02-01

218592 182361 2,814 79 26 51 h-index citations g-index papers 80 80 80 2808 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Neuroendocrine control of food intake. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 158-168.	1.1	522
2	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology, 2011, 165, 383-392.	1.9	322
3	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
4	Delayed Remission after Transsphenoidal Surgery in Patients with Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 601-610.	1.8	133
5	Potential Cardiac Valve Effects of Dopamine Agonists in Hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1025-1033.	1.8	122
6	Cushing's syndrome and pregnancy outcomes: a systematic review of published cases. Endocrine, 2017, 55, 555-563.	1.1	87
7	A reappraisal of the medical therapy with steroidogenesis inhibitors in <scp>C</scp> ushing's syndrome. Clinical Endocrinology, 2012, 77, 735-742.	1.2	83
8	Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e12-e22.	1.8	69
9	Small cerebellar cortex volume in patients with active Cushing's syndrome. European Journal of Endocrinology, 2014, 171, 461-469.	1.9	55
10	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	1.9	53
11	Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice. European Journal of Endocrinology, 2012, 167, 337-342.	1.9	50
12	Clinical consequences of Cushing's syndrome. Pituitary, 2012, 15, 319-329.	1.6	50
13	Adipokines and Cardiovascular Risk in Cushing's Syndrome. Neuroendocrinology, 2012, 95, 187-206.	1.2	47
14	Impaired decisionâ€making and selective cortical frontal thinning in Cushing's syndrome. Clinical Endocrinology, 2014, 81, 826-833.	1.2	46
15	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
16	Worse Healthâ€Related Quality of Life at longâ€term followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp> . Clinical Endocrinology, 2018, 88, 787-798.	1.2	40
17	Dyslipidemia and Chronic Inflammation Markers Are Correlated with Telomere Length Shortening in Cushing's Syndrome. PLoS ONE, 2015, 10, e0120185.	1.1	39
18	Molecular profiling for acromegaly treatment: a validation study. Endocrine-Related Cancer, 2020, 27, 375-389.	1.6	39

#	Article	IF	Citations
19	MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease. European Journal of Endocrinology, 2017, 177, R13-R26.	1.9	37
20	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37
21	Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome. European Journal of Endocrinology, 2015, 173, 765-775.	1.9	35
22	Update on quality of life in patients with acromegaly. Pituitary, 2017, 20, 185-188.	1.6	35
23	Psychiatric and neurocognitive consequences of endogenous hypercortisolism. Journal of Internal Medicine, 2020, 288, 168-182.	2.7	35
24	Impaired decision making and delayed memory are related with anxiety and depressive symptoms in acromegaly. Endocrine, 2015, 50, 756-763.	1.1	33
25	Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	1.9	32
26	Health-Related Quality of Life in Pituitary Diseases. Endocrinology and Metabolism Clinics of North America, 2015, 44, 161-170.	1.2	29
27	Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels. European Journal of Endocrinology, 2017, 176, 221-231.	1.9	28
28	Quality of Life in Patients With Cushing's Disease. Frontiers in Endocrinology, 2019, 10, 862.	1.5	28
29	Telomere length analysis in Cushing's syndrome. European Journal of Endocrinology, 2014, 171, 21-29.	1.9	25
30	Clinical presentation and etiology of Cushing's syndrome: Data from <scp>ERCUSYN</scp> . Journal of Neuroendocrinology, 2022, 34, .	1.2	25
31	Morbidity of Cushing's Syndrome and Impact ofÂTreatment. Endocrinology and Metabolism Clinics of North America, 2018, 47, 299-311.	1.2	22
32	Quality of Life in Cushing's disease: A long term issue?. Annales D'Endocrinologie, 2018, 79, 132-137.	0.6	22
33	A polymorphism in the <i>CYP17A1</i> gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clinical Endocrinology, 2017, 87, 433-439.	1.2	19
34	Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing's Syndrome: Preliminary Study. BioMed Research International, 2017, 2017, 1-7.	0.9	19
35	El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la EndocrinologÃa espaA±ola por la medicina individualizada y la investigación traslacional. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 274-284.	0.8	18
36	Thigh Muscle Fat Infiltration Is Associated With Impaired Physical Performance Despite Remission in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2039-e2049.	1.8	17

#	Article	IF	Citations
37	Quality of life in Cushing's syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101505.	2.2	16
38	Reduction of trabecular and cortical volumetric bone mineral density at the proximal femur in patients with acromegaly. European Journal of Endocrinology, 2016, 174, 107-114.	1.9	15
39	Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly. Endocrine Connections, 2019, 8, 39-49.	0.8	15
40	PronÃ ³ stico del paciente tratado de sÃndrome de Cushing. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2014, 61, 52-61.	0.8	13
41	The Molecular Registry of Pituitary Adenomas (REMAH): A bet by Spanish Endocrinology for the future of individualized medicine and translational research. EndocrinologÃa Y Nutrición (English Edition), 2016, 63, 274-284.	0.5	13
42	Data mining analyses for precision medicine in acromegaly: a proof of concept. Scientific Reports, 2022, 12, .	1.6	11
43	Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly. Endocrine, 2016, 53, 860-864.	1.1	10
44	Quality of life impairment after a diagnosis of Cushing's syndrome. Pituitary, 2022, 25, 768-771.	1.6	10
45	Prognosis of patients treated for Cushing syndrome. EndocrinologÃa Y Nutrición (English Edition), 2014, 61, 52-61.	0.5	9
46	Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. Clinical Endocrinology, 2017, 86, 214-222.	1.2	9
47	Patient-Centered Outcomes with Pituitary and Parasellar Disease. Neuroendocrinology, 2020, 110, 882-888.	1.2	9
48	Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GHâ€producing adenomas. Clinical Endocrinology, 2021, 94, 811-819.	1.2	9
49	Acromegalia y gestaci \tilde{A}^3 n. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2013, 60, 1-3.	0.8	8
50	Prevalence of sarcopenia after remission of hypercortisolism and its impact on HRQoL. Clinical Endocrinology, 2021, 95, 735-743.	1.2	8
51	Intramuscular fatty infiltration and physical function in controlled acromegaly. European Journal of Endocrinology, 2021, 185, 167-177.	1.9	7
52	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary, 2022, 25, 64-73.	1.6	7
53	Improving Quality of Life in Patients with Pituitary Tumours. European Endocrinology, 2010, 9, 32.	0.8	7
54	Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response. Biomedicines, 2022, 10, 460.	1.4	7

#	Article	IF	CITATIONS
55	The value of a European registry for pituitary adenomas: The example of Cushing's syndrome registry. Annales D'Endocrinologie, 2012, 73, 83-89.	0.6	6
56	Unmet needs in Cushing's syndrome: the patients' perspective. Endocrine Connections, 2022, 11, .	0.8	6
57	PatologÃa hipofisaria y gestación. Endocrinologia, Diabetes Y NutriciÓn, 2021, 68, 184-195.	0.1	3
58	Pituitary disease and pregnancy. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2021, 68, 184-195.	0.1	3
59	Quality of life in patients with pituitary tumors. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 67-73.	0.6	1
60	Complication Rates after Endoscopic Transsphenoidal Surgery for ACTH-Secreting Pituitary Adenomas: A Comparative Analysis with GH and Nonfunctioning Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, e274-e283.	0.4	1
61	Consequences of Cushing's syndrome: Health versus personal costs. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	1
62	Long-Term Effects of Prior Cushing's Syndrome. , 2017, , 199-224.		0
63	Quality of life in pituitary tumors. , 2021, , 669-677.		0
64	Increased serum levels of the Wnt antagonist Dicckopf-1 (DKK1) and impaired trabecular bone mineral density using QCT scan in acromegalic patients. Endocrine Abstracts, 0, , .	0.0	0
65	Serum brain-derived neurotrophic factor in Cushing [apos]s syndrome patients. Endocrine Abstracts, 0, , .	0.0	0
66	Psychopathology, memory and quality of life in Cushing's syndrome. Endocrine Abstracts, 0, , .	0.0	0
67	Relationship between circulating microRNAs and bone mineral density in patients with active acromegaly. Endocrine Abstracts, 0, , .	0.0	O
68	Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing's syndrome. Data from ERCUSYN. Endocrine Abstracts, 0, , .	0.0	0
69	Molecular profiling of non-functioning pituitary adenomas does not support pharmacological therapeutic options. Endocrine Abstracts, 0, , .	0.0	0
70	Psychopathology in Cushing's disease and acromegaly. Endocrine Abstracts, 0, , .	0.0	0
71	MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission. Journal of the Endocrine Society, 2019, 3, .	0.1	0
72	MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI. Journal of the Endocrine Society, 2019, 3, .	0.1	0

#	Article	lF	Citations
73	Muscle dysfunction is associated with poor quality of life in patients with Cushing's syndrome long-term after remission. Endocrine Abstracts, 0, , .	0.0	0
74	Skeletal muscle fatty infiltration in the thigh, as assessed by MRI T2-weighted and 3-point Dixon sequences, is associated with poor performance on muscle function testing in patients with Cushing's syndrome in remission. Endocrine Abstracts, 0, , .	0.0	0
75	European observational study of ketoconazole for endogenous cushing's syndrome in collaboration with European registry on cushing's syndrome ERCUSYN: PASS ketoconazole study design and rationale. Endocrine Abstracts, 0, , .	0.0	0
76	Data mining analyses for precision medicine in acromegaly. Endocrine Abstracts, 0, , .	0.0	0
77	The cushing's collaborative patient survey results. Endocrine Abstracts, 0, , .	0.0	0
78	Etiology and extent of impaired quality of life, fatigue and affective, cognitive, and emotional dysfunction in patients with cushing $\hat{a} \in \mathbb{N}$ syndrome $\hat{a} \in \mathbb{N}$ The IQFACE-CS study. Endocrine Abstracts, 0, , .	0.0	0
79	Gender dimorphism of intramuscular fatty infiltration and related muscle dysfunction in patients with long-term control of acromegaly. Endocrine Abstracts, 0, , .	0.0	0